Jump to content

Said Darwazah

The comprehensive free global encyclopedia of CEOs, corporate leadership, and business excellence
Said Darwazah
BornMay 1957
NationalityJordanian
EducationPurdue University (BS, Industrial Engineering, 1980)
INSEAD (MBA, 1984)
OccupationBusiness executive
CompanyHikma Pharmaceuticals
TitleChief Executive Officer, Hikma Pharmaceuticals
SpouseMariana Darwazah

Said Samih Taleb Darwazah (born May 1957) is a Jordanian business executive and former government minister who is the chief executive officer of Hikma Pharmaceuticals, the London-listed multinational maker of generic and branded medicines founded by his father, Samih Darwazah, in Amman in 1978.[1][2] He has held the chief executive role three times: from July 2007 to February 2018, on an acting basis from 2022 to 2023, and again since December 15, 2025.[3]

Darwazah joined the family business around 1980, when it was a small Jordanian manufacturer with about 50 employees, and in 1991 led the team that bought West-Ward Pharmaceuticals in New Jersey, the company's entry into the United States market.[4] Darwazah ran the group holding company from 1994 to 2003, then left to serve as Jordan's Minister of Health from 2003 to 2006.[5]

During Darwazah's first spell as chief executive, the company grew from a company that had listed on the London Stock Exchange in 2005 with $262 million of revenue into a FTSE 100 constituent with revenue of about $1.95 billion in 2016. Much of that growth came through acquisitions in Egypt, Europe and the United States, the largest being the purchase of Roxane Laboratories from Boehringer Ingelheim, agreed in 2015 and completed in 2016.[6][7] In May 2014 he succeeded his father as chairman. From February 2018 he was executive chairman, a role he gave up on February 26, 2026, when the board split the chair and chief executive posts and appointed Victoria Hull as non-executive chair.[8][9][10]

Outside Hikma, Darwazah chairs the board of Royal Jordanian, the national airline, and the Queen Rania Foundation. He founded Jordan's Health Care Accreditation Council and is vice chairman of Capital Bank of Jordan.[3] Through a family trust he holds an interest in Darhold Limited, Hikma's largest shareholder.[11]

Early life and education

Said Darwazah is the son of Samih Darwazah and his wife Samira. His parents met as students at the American University of Beirut, where his father took a degree in pharmacy in 1954.[2] Samih Darwazah was born in Nablus in 1930 and grew up mostly in Jaffa, where his own father was a merchant. The family moved to Jordan in 1948. After a master's degree in industrial pharmacy at the St. Louis College of Pharmacy in Missouri, held on a Fulbright scholarship, Samih worked for Eli Lilly from 1964 to 1976, first in the United States and then in the company's Middle East marketing division. He returned to Jordan and founded the company in 1978, when he was 48. According to Hikma, his children joined the business "in its early days". Samih had four children, and 11 grandchildren at the time of his death in 2015.[2] Companies House records Said Darwazah's full name as Said Samih Taleb Darwazah and his date of birth as May 1957.[1]

Darwazah studied industrial engineering at Purdue University in the United States and graduated with a Bachelor of Science in Industrial Engineering in 1980.[4] After several years in the family business Darwazah took an MBA at INSEAD in France, finishing in 1984.[4][12]

Career

Early years at Hikma and West-Ward (1980 to 1994)

Purdue's alumni profile says Darwazah joined his father and brother at Hikma in 1980. At that time the company was a small family-owned manufacturer with sales of around $1 million and about 50 employees.[4] Hikma's current biography gives 1981 as the year he joined.[3] He started as an industrial engineer in manufacturing. After his INSEAD MBA he moved into sales and marketing.[4]

In 1991 Darwazah led a company team to the United States, where it acquired West-Ward Pharmaceuticals Corp., a generic drug manufacturer in New Jersey. He stayed on as chief executive and president of West-Ward until 1994.[4] The company describes the West-Ward deal as its entry into the US market. It also says that by the 1980s the group had set up the first FDA-inspected manufacturing plant in the Middle East and bought land in Portugal for a sterile injectables plant.[13] West-Ward later became the base of the group's US business, and a 2015 board biography of Darwazah credits Darwazah with a "key role" in the West-Ward acquisition and in building the injectables business in Europe and the Middle East and North Africa (MENA) region.[5]

Group chairman and chief executive (1994 to 2003)

According to Hikma, Darwazah was chairman and chief executive of the group holding company from 1994 to 2003.[3][5] Purdue's profile dates his appointment as Hikma's chairman and chief executive to 1995.[4] In the company's own account of the 1990s, the group expanded through acquisitions in Tunisia and Saudi Arabia while continuing to grow its Portuguese injectables operation.[13] The company's 2015 board biography says that, under Darwazah's leadership, the company's plants in the United States, Jordan and Portugal gained approval from the US Food and Drug Administration.[5]

Minister of Health of Jordan (2003 to 2006)

Darwazah joined the Jordanian cabinet as Minister of Health in 2003.[4] Hikma and Royal Jordanian both give his term as 2003 to 2006.[5][14] While Darwazah was in government, the company floated on the London Stock Exchange in 2005, raising gross proceeds of US$124 million.[13] At the listing it had six manufacturing plants, fewer than 2,000 employees and $262 million of revenue.[6] By 2016 its shares were also quoted on NASDAQ Dubai under the ticker HIK.[15]

Chief executive of Hikma Pharmaceuticals (2007 to 2018)

Darwazah was appointed chief executive of Hikma Pharmaceuticals PLC on July 1, 2007. Companies House lists the same date as the start of his directorship of the listed company.[1][3] In 2013 Darwazah said the company had entered the Egyptian market in 2007 and had been "rapidly growing our presence" since.[16]

According to Purdue's 2011 profile, the company had over 7,500 employees under Darwazah and expected sales above $1 billion in 2012. It had manufacturing operations in the United States, Portugal, Germany, Italy, Saudi Arabia, Morocco, Algeria, Tunisia, Sudan and Jordan.[4] In November 2010 he gave the keynote address at the third annual Harvard School of Public Health MENA conference. His talk covered population growth, rising life expectancy, chronic disease and the affordability of healthcare in the region.[17]

On February 11, 2014, Hikma announced that Samih Darwazah, then non-executive chairman, would retire from the board at the annual general meeting on May 15, 2014, and become honorary life president. Said Darwazah would become chairman and chief executive.[8] His father said that Said "and his very efficient team have significantly improved the business over the last seven years".[8] Combining the two roles departed from the UK Corporate Governance Code, and the company later said the board had consulted shareholders before the appointment. At the same time Robert Pickering became senior independent director, and Darwazah said Hikma would "continue to have, a very strong senior independent director".[11][8]

Hikma joined the FTSE 100 index in March 2015 and employed about 7,000 people that year.[2] Samih Darwazah died in London on May 15, 2015, at the age of 85.[2] The Roxane Laboratories acquisition, completed in February 2016, made the group considerably larger in the US generics market. Group revenue rose 35 percent to $1,950 million in 2016.[7] In October 2016 Darwazah received the "Leader of the Year" award at the third Global Generics and Biosimilars Awards in Barcelona.[15]

In 2017 the US business ran into trouble. Hikma's US Generics business, and West-Ward Columbus (the former Roxane) in particular, faced intense pricing pressure. On May 11, 2017, the FDA issued a complete response letter on Hikma's application for a generic version of GlaxoSmithKline's Advair Diskus inhaler, delaying approval. The FDA later upheld its decision through the dispute resolution process and asked for a new clinical endpoint study.[18] For 2017 Hikma reported core revenue of $1,936 million and an operating loss of $747 million. The loss was mainly due to a $920 million impairment of West-Ward Columbus intangible assets and a $164 million impairment of property, plant and equipment.[19]

Executive chairman (2018 to 2026)

On February 20, 2018, Hikma appointed Sigurdur (Siggi) Olafsson, formerly head of Teva's global generics business, as chief executive with immediate effect. Darwazah became executive chairman.[20] Under the new arrangement the executive committee reported to Olafsson, and Olafsson reported to Darwazah. Darwazah was to lead the board and to "guide, oversee, and engage with the Chief Executive" on strategy.[20] Presenting the 2017 results the following month, Darwazah said the company was "making transformational changes across the Group" to be more competitive.[19] Hikma's 2025 annual report says the executive chairman role was created in February 2018 when the new chief executive arrived. Before that, Darwazah had been executive chairman and CEO.[11]

In March 2018 Harvard Business School published a case study on Hikma by Lynn Paine, Suraj Srinivasan and Gamze Yucaoglu. It was written for courses on corporate governance and boards and covered the company's move from family business to public company. Darwazah said students would "learn about establishing strong corporate governance from our experience of transitioning from a family business to a public company".[21]

Acting chief executive (2022 to 2023)

Olafsson resigned as chief executive on May 24, 2022, "to pursue other opportunities", and left on June 24, 2022. Darwazah took on all chief executive responsibilities while the board ran an externally facilitated search for a successor. Darwazah worked with the executive committee, including the presidents of the three divisions.[22] When he reported 2022 results as executive chairman and chief executive, revenue was $2,517 million, down 1 percent, and reported operating profit was $282 million, down 52 percent because of non-cash impairments. He said the Injectables and Branded businesses had "helped to partially offset the decline in Generics".[23]

On April 12, 2023, Hikma named Riad Mishlawi, president of the Injectables business since 2011, as chief executive from September 1, 2023. Darwazah then returned to being executive chairman. He said Mishlawi was "the standout candidate" after "an extensive, global search".[24]

Return as chief executive (2025 to present)

On December 15, 2025, Hikma announced that Mishlawi was stepping down as chief executive and leaving the board "by mutual agreement", and that Darwazah would assume all chief executive responsibilities with immediate effect. Chief financial officer Khalid Nabilsi joined the board and took on wider management duties. Victoria Hull, then senior independent director, said the board would launch a search for a new chief executive "in due course".[25] For the period in which Darwazah combined the two roles, the board said it reviewed its delegation of authority framework "to ensure that no one individual had unfettered powers of decision-making".[11]

With the 2025 results on February 26, 2026, Darwazah said he would "relinquish my Executive Chairman responsibilities and focus fully on being CEO".[9] The nomination committee said the change would let him concentrate on the chief executive role "for the next two years". Separating the chair and chief executive roles brought the company into compliance with the UK Corporate Governance Code on the division of responsibilities. Hull became non-executive chair. Two deputy chief executive posts were created: Mazen Darwazah for MENA and Nabilsi for North America and Europe.[11][10] On September 24, 2026, Hikma named Rebecca Hall of ViiV Healthcare as chief financial officer from the first quarter of 2027. Darwazah, as chief executive, said she would bring "financial and operational discipline".[26] As of October 2026, Hikma lists Darwazah as chief executive officer and Hull as chair.[3][10]

In a May 2026 article published by Hikma, Darwazah wrote: "I am back in the CEO role because I know we can go much further." Darwazah set an aspiration for the company to become a $5 billion revenue company by 2030.[27] He acknowledged that the Injectables business was "navigating a period of transition", with more competition on established products and heavier investment, including the expansion of its plant in Bedford, Ohio. He wrote that the company was "not managing this business for short-term margin optimisation".[27] In the annual report he said full commercial production at Bedford was expected to begin in 2028.[6]

Leadership and management style

When he became chairman and chief executive in 2014, Darwazah described his own approach: "Those of you who know me will know that my style is to always listen to others and understand their views, with the aim of making the best decision in a consensual manner." He said his role would "continue to focus on overall group strategy" and that the divisional heads would continue to run their businesses.[8] The 2018 and 2022 arrangements followed the same pattern. In each, Darwazah worked through the divisional presidents and executive committee instead of taking over divisional management.[20][22]

Hikma's board has cited continuity and relationships as reasons for keeping him in an executive role at the top of the company. Its 2025 annual report says Darwazah has been "a driving force behind the strategic success of the business since 2007". It also says many of the company's political and commercial relationships in MENA, Asia and parts of continental Europe "are built on the long-term trust and respect for the Darwazah family".[11] The report lists his 2025 activities as executive chairman: meetings with investors at the Jefferies Global Healthcare Conference, meetings with large shareholders after Mishlawi's departure, meetings with officials in Jordan including the US ambassador, and attending the London Stock Exchange for the 20th anniversary of Hikma's listing.[11] Shareholders voted 96.6 percent in favour of his re-election at the 2025 annual general meeting.[11]

The board added safeguards while he held a combined or executive chair role. The independent non-executive directors met privately after every board meeting, and the senior independent director shared responsibility with Darwazah for succession planning, board reviews and the board agenda.[11]

Darwazah has argued that the company should be judged on access to medicines as well as financial returns. In his May 2026 article he wrote that "being a responsible business means access to medicines is central to every decision we make". Darwazah described its place in MENA, where it became the largest pharmaceutical company by sales in 2025 after ranking fifth in 2020, as "an underappreciated one".[27]

Major deals and strategic decisions

  • EPCI, Egypt (2013): In January 2013 Hikma agreed to buy the Egyptian Company for Pharmaceuticals & Chemical Industries for EGP 142.4 million, about US$22.2 million at the time. Darwazah said the company would "pursue other value-creating acquisition opportunities in the region".[16]
  • Bedford Laboratories and Ben Venue (2014): On May 28, 2014, Hikma agreed to buy the assets of Bedford Laboratories, the US generic injectables business of Boehringer Ingelheim's Ben Venue Laboratories. The price was up to $300 million: $225 million up front and up to $75 million in contingent payments over five years. Darwazah said the deal would benefit patients "by bringing back products to the market that are currently in short supply".[28] In July 2014 Hikma agreed to take over substantially all of the Ben Venue manufacturing site in Bedford, Ohio, where manufacturing had stopped, with no additional consideration.[29]
  • Roxane Laboratories (2015 to 2016): On July 28, 2015, Hikma agreed to buy Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. for $1.18 billion in cash plus 40 million new Hikma shares, a combined value of about US$2.65 billion at the time, plus up to $125 million in contingent payments. Darwazah said the deal would transform "our position and scale in the US generics market".[30] In February 2016, after Boehringer provided new information showing weaker 2015 performance at Roxane, the cash element was cut by $535 million to $647 million. The share element was unchanged.[31] The deal closed on February 29, 2016, leaving Boehringer with about 16.71 percent of Hikma.[32] Darwazah called it "our largest acquisition to date".[7] The business, renamed West-Ward Columbus, accounted for most of the impairments in 2017.[19]
  • EIMC United Pharmaceuticals (2015): In September 2015 Hikma agreed to buy 98.09 percent of EIMC United Pharmaceuticals, an Egyptian oncology manufacturer. The purchase was completed in 2016.[33][7]
  • Executive chairman period (2018 to 2025): While Darwazah was executive chairman, Hikma agreed to buy Custopharm for $375 million plus up to $50 million in contingent payments (September 2021) and the Canadian assets of Teligent for $45.75 million (January 2022). It also agreed to buy parts of Xellia Pharmaceuticals' US business, including a plant in Cleveland, Ohio, for $135 million plus up to $50 million in contingent payments (June 2024), and the MENA rights to 17 Takeda brands (December 2024).[34][35][36][37] In March 2021 Hikma and GlaxoSmithKline ended talks on a possible purchase of GSK's businesses in Egypt and Tunisia.[38]
  • Share buyback (2026): With the 2025 results, Darwazah announced a $250 million share buyback to run through 2026 and a 5 percent increase in the total dividend.[9]

Financial and market performance

The figures below come from Hikma's own reports and cover the main points of Darwazah's time in charge.

Hikma Pharmaceuticals revenue at selected points
Year Revenue Darwazah's role Notes
2005 $262 million Minister of Health (outside Hikma) Year of London listing[6]
2016 $1,950 million Chairman and chief executive Up 35 percent, with 10 months of Roxane[7]
2017 $1,936 million (core) Chairman and chief executive Reported operating loss of $747 million[19]
2022 $2,517 million Executive chairman and acting chief executive Reported operating profit down 52 percent[23]
2025 $3,349 million Executive chairman, chief executive from December 15 Up 7 percent; core operating profit $741 million[9]

Headcount grew from fewer than 2,000 at the 2005 listing to about 7,000 in 2015, 9,100 in 2024 and more than 9,300 at the time of the 2025 annual report.[6][2][39] Over the same period the number of manufacturing plants rose from six to 29.[6] For the first half of 2026, his first full half-year back as chief executive, Hikma reported revenue of $1,728 million, up 4 percent, and core operating profit of $405 million, up 9 percent, and kept its full-year guidance unchanged.[40]

Hikma's remuneration committee said in its 2025 report that the company's total shareholder return over the 10 years to December 31, 2025, "trailed the FTSE comparator and the sector peer groups".[11]

Remuneration and shareholding

Darwazah's base salary was $1,040,000 in 2025 and rose 2 percent to $1,060,800 for 2026. His total single-figure remuneration was $3,077,622 for 2025, against $3,537,622 for 2024, $4,501,217 for 2018 and $6,308,238 for 2016.[11] He has a rolling service contract dated July 1, 2007, with 12 months' notice.[11]

Darwazah, Mazen Darwazah and director Ali Al-Husry are directors and shareholders of Darhold Limited, which held 60,000,000 Hikma shares as of December 31, 2025. Darwazah holds 26.76 percent of Darhold through a family trust in which he has a beneficial interest. Including shares held personally or by connected persons, the company reported Darwazah's total effective interest as 17,566,790 shares. During 2025 Darwazah bought 400,000 shares on June 11 and 130,000 on July 11 in the market.[11]

Board memberships and outside roles

On June 19, 2016, Darwazah was appointed to the board of Royal Jordanian as a representative of the Government Shareholdings' Management Company, which owned 60.2 percent of the airline. The board elected him chairman on June 21, 2016, replacing Suleiman Hafez.[14][41] In October 2020, after chief executive Stefan Pichler retired, the airline named Darwazah its interim chief executive as well.[42] As of October 2026, Hikma lists him as chairman of Royal Jordanian Airlines.[3]

His other current appointments, according to Hikma, are chairman of the Queen Rania Foundation, chairman and founder of the Health Care Accreditation Council in Jordan, vice chairman of Capital Bank of Jordan and trustee of the American University of Beirut.[3] The Queen Rania Foundation focuses on education for young people, including technology in education and online learning.[14]

He has previously been chairman of the Jordan University of Science and Technology and a board member of the Central Bank of Jordan, Babson College and INSEAD.[3] In 2016 he chaired the board of trustees of the Jordan University of Science and Technology.[41] Purdue's profile also lists him as a former trustee of the University of Jordan and of International College in Lebanon, and as vice chairman of the Royal Health Awareness Society in Jordan.[4]

Personal life

Darwazah is married to Mariana Darwazah.[12] Companies House lists his country of residence as Jordan.[1] The company said Samih Darwazah "valued family above all else"; at his death in 2015 he had four children and 11 grandchildren.[2] Mazen Darwazah, Hikma's executive vice chairman and deputy chief executive for MENA, has worked at the company since 1985 and sits on the board with Said Darwazah.[43]

Philanthropy

Purdue's profile says Darwazah's main interest is promoting better health. It describes the Health Care Accreditation Council, which he founded, as a non-profit that accredits healthcare providers and works to improve standards.[4] According to the 2016 Royal Jordanian announcement, Darwazah co-founded the Samih Darwazah Center for Innovation Management and Entrepreneurship at the American University of Beirut.[14] The centre opened at the university's Suliman S. Olayan School of Business on January 14, 2011, funded by a grant from the Samih Darwazah Foundation.[44] No amounts for his personal giving have been published in the sources reviewed.

Recognition

  • 2011: Outstanding Industrial Engineer award, Purdue University School of Industrial Engineering[4]
  • 2016: "Leader of the Year", Global Generics and Biosimilars Awards, Barcelona (October 4, 2016)[15]
  • 2024: Named on the Arabian Business list of healthcare visionaries, and ranked second on the Forbes Middle East Top 100 Healthcare Leaders list[39]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 <ref>"Hikma Pharmaceuticals Public Limited Company: officers".Companies House.Retrieved October 29, 2026.</ref>
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 <ref>"Hikma founder and honorary life president Samih Darwazah passes away".Hikma Pharmaceuticals.May 18, 2015.Retrieved October 29, 2026.</ref>
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 <ref>"Said Darwazah".Hikma Pharmaceuticals.Retrieved October 29, 2026.</ref>
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 <ref>"Said S. Darwazah".Edwardson School of Industrial Engineering, Purdue University.Retrieved October 29, 2026.</ref>
  5. ↑ 5.0 5.1 5.2 5.3 5.4 <ref>"Board of directors".Hikma Pharmaceuticals.2015.Retrieved October 29, 2026.</ref>
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 <ref>"Annual Report 2025: Executive Chairman and Chief Executive Officer's statement".Hikma Pharmaceuticals.February 2026.Retrieved October 29, 2026.</ref>
  7. ↑ 7.0 7.1 7.2 7.3 7.4 <ref>"Hikma delivers a solid financial performance in 2016 and makes significant strategic progress".Hikma Pharmaceuticals.March 15, 2017.Retrieved October 29, 2026.</ref>
  8. ↑ 8.0 8.1 8.2 8.3 8.4 <ref>"Board changes".Hikma Pharmaceuticals.February 11, 2014.Retrieved October 29, 2026.</ref>
  9. ↑ 9.0 9.1 9.2 9.3 <ref>"Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes".Hikma Pharmaceuticals.February 26, 2026.Retrieved October 29, 2026.</ref>
  10. ↑ 10.0 10.1 10.2 <ref>"Victoria Hull".Hikma Pharmaceuticals.Retrieved October 29, 2026.</ref>
  11. ↑ 11.00 11.01 11.02 11.03 11.04 11.05 11.06 11.07 11.08 11.09 11.10 11.11 11.12 <ref>"Annual Report 2025: Corporate governance".Hikma Pharmaceuticals.February 2026.Retrieved October 29, 2026.</ref>
  12. ↑ 12.0 12.1 <ref>"Said Darwazah MBA'84".INSEAD.Retrieved October 29, 2026.</ref>
  13. ↑ 13.0 13.1 13.2 <ref>"History".Hikma Pharmaceuticals.Retrieved October 29, 2026.</ref>
  14. ↑ 14.0 14.1 14.2 14.3 <ref>"Said Darwazeh elected RJ Chairman of the Board of Directors; Suleiman Obeidat appointed a board member".Al Bawaba (Royal Jordanian press release).June 22, 2016.Retrieved October 29, 2026.</ref>
  15. ↑ 15.0 15.1 15.2 <ref>"Said Darwazah, Chairman and CEO of Hikma, awarded Global Generics "Leader of the Year"".Hikma Pharmaceuticals.October 12, 2016.Retrieved October 29, 2026.</ref>
  16. ↑ 16.0 16.1 <ref>"Hikma agrees to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries, strengthening its position in the large and fast growing Egyptian market".Hikma Pharmaceuticals.January 9, 2013.Retrieved October 29, 2026.</ref>
  17. ↑ <ref>"Hikma CEO speaks at Harvard School of Public Health's MENA Conference".Hikma Pharmaceuticals.December 10, 2010.Retrieved October 29, 2026.</ref>
  18. ↑ <ref>"Hikma provides an update on the status of its ANDA for generic Advair Diskus".Hikma Pharmaceuticals.March 12, 2018.Retrieved October 29, 2026.</ref>
  19. ↑ 19.0 19.1 19.2 19.3 <ref>"Hikma reports 2017 full year results".Hikma Pharmaceuticals.March 14, 2018.Retrieved October 29, 2026.</ref>
  20. ↑ 20.0 20.1 20.2 <ref>"Sigurdur Olafsson appointed Chief Executive Officer".Hikma Pharmaceuticals.February 20, 2018.Retrieved October 29, 2026.</ref>
  21. ↑ <ref>"Hikma becomes Harvard Business School Case Study as part of Corporate Governance and Making Boards Effective Modules".Hikma Pharmaceuticals.March 6, 2018.Retrieved October 29, 2026.</ref>
  22. ↑ 22.0 22.1 <ref>"Siggi Olafsson to step down as Chief Executive".Hikma Pharmaceuticals.May 24, 2022.Retrieved October 29, 2026.</ref>
  23. ↑ 23.0 23.1 <ref>"Hikma delivers a resilient underlying performance in 2022".Hikma Pharmaceuticals.February 23, 2023.Retrieved October 29, 2026.</ref>
  24. ↑ <ref>"Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC".Hikma Pharmaceuticals.April 12, 2023.Retrieved October 29, 2026.</ref>
  25. ↑ <ref>"Hikma announces CEO change and Board appointment".Hikma Pharmaceuticals.December 15, 2025.Retrieved October 29, 2026.</ref>
  26. ↑ <ref>"Hikma appoints Rebecca Hall as Chief Financial Officer".Hikma Pharmaceuticals.September 24, 2026.Retrieved October 29, 2026.</ref>
  27. ↑ 27.0 27.1 27.2 <ref>"Why the world needs more companies like Hikma. By Said Darwazah, Chief Executive Officer".Hikma Pharmaceuticals.May 7, 2026.Retrieved October 29, 2026.</ref>
  28. ↑ <ref>"Hikma Pharmaceuticals PLC: Acquisition of Bedford Laboratories".Hikma Pharmaceuticals.May 28, 2014.Retrieved October 29, 2026.</ref>
  29. ↑ <ref>"Hikma agrees to acquire Ben Venue manufacturing site adding R&D capabilities and capacity".Hikma Pharmaceuticals.July 24, 2014.Retrieved October 29, 2026.</ref>
  30. ↑ <ref>"Hikma acquires Roxane Laboratories, transforming its position in the US generics market".Hikma Pharmaceuticals.July 28, 2015.Retrieved October 29, 2026.</ref>
  31. ↑ <ref>"Hikma announces revised terms for previously announced acquisition of Roxane Laboratories".Hikma Pharmaceuticals.February 10, 2016.Retrieved October 29, 2026.</ref>
  32. ↑ <ref>"Hikma announces the close of the Roxane Laboratories acquisition".Hikma Pharmaceuticals.February 29, 2016.Retrieved October 29, 2026.</ref>
  33. ↑ <ref>"Hikma agrees to acquire EIMC United Pharmaceuticals, strengthening its position in the large and fast growing Egyptian market".Hikma Pharmaceuticals.September 8, 2015.Retrieved October 29, 2026.</ref>
  34. ↑ <ref>"Hikma strengthens US Injectables business through acquisition of Custopharm".Hikma Pharmaceuticals.September 27, 2021.Retrieved October 29, 2026.</ref>
  35. ↑ <ref>"Hikma expands into Canada with acquisition of Teligent sterile injectable assets".Hikma Pharmaceuticals.January 17, 2022.Retrieved October 29, 2026.</ref>
  36. ↑ <ref>"Hikma acquires Xellia's differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D".Hikma Pharmaceuticals.June 17, 2024.Retrieved October 29, 2026.</ref>
  37. ↑ <ref>"Hikma acquires the rights to a portfolio of Takeda brands for the MENA region".Hikma Pharmaceuticals.December 19, 2024.Retrieved October 29, 2026.</ref>
  38. ↑ <ref>"Hikma and GSK agree to cease potential acquisition discussions in Egypt and Tunisia".Hikma Pharmaceuticals.March 11, 2021.Retrieved October 29, 2026.</ref>
  39. ↑ 39.0 39.1 <ref>"Hikma's leadership receives prestigious recognitions in 2024".Hikma Pharmaceuticals.October 22, 2024.Retrieved October 29, 2026.</ref>
  40. ↑ <ref>"Hikma delivers a solid H1 performance and reiterates full year outlook".Hikma Pharmaceuticals.August 6, 2026.Retrieved October 29, 2026.</ref>
  41. ↑ 41.0 41.1 <ref>"RJ board names Darwazeh as chairman".June 23, 2016.Retrieved October 29, 2026.</ref>
  42. ↑ <ref>Kaminski-Morrow, David."Royal Jordanian seeks new chief executive after Pichler retires".October 19, 2020.Retrieved October 29, 2026.</ref>
  43. ↑ <ref>"Mazen Darwazeh".Hikma Pharmaceuticals.Retrieved October 29, 2026.</ref>
  44. ↑ <ref>"Samih Darwazah Center for Innovation Management and Entrepreneurship launched at American University of Beirut".Hikma Pharmaceuticals.January 14, 2011.Retrieved October 29, 2026.</ref>
Retrieved from "https://ceo.wiki/index.php?title=Said_Darwazah&oldid=9371"